Eloxx Pharmaceuticals Inc ELOX

$11.01 +4.81 (77.58%)

Valuation

Market cap
1,877,000
Revenue TTM
$0
Net income TTM
$-6,000,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
283,900
Avg volume
8,122
Day's range
$8.25 – $11.60
Shares out
5,072,000
Stochastic %K
94%
Beta
-1,907.33
Analysts
Strong Buy
Price target
$30.00

Price

Company profile

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alpo...

Show more

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations. It has collaboration with Almirall, S.A. to develop and commercialize ZKN-013, an oral ribosome modulating agent for the treatment of rare skin diseases, such as recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa with nonsense mutations. Eloxx Pharmaceuticals, Inc. was incorporated in 1999 and is based in Arlington, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
781 577 5300
Website
https://www.eloxxpharma.com
Address
P.O. Box 274, Arlington, United States

Latest news

Stocktwits

NVDAMillionaire Sep 24, 9:31 AM
$ELOX Outstanding article that hits the mark on ELOX's current state. So if you want to refresh your ELOX insights or learn about ELOX from scratch, this is a must read. https://everyticker.com/quote/ELOX/analysis/elox-pharmaceuticals-a-62-million-gamble-on-a-single-trial-nasdaq-elox
0 replies
MingChoo Sep 13, 2:11 PM
$ELOX Upside potential8
0 replies
BioTuesdays Sep 11, 9:47 PM
$ELOX has announced that the first two patients have been dosed in its Phase 2b EXACT Study evaluating exaluren in patients with nonsense mutation Alport syndrome (NMAS). https://biotuesdays.com/2026/09/11/eloxx-announces-first-patients-dosed-in-study-of-exaluren-in-nmas/
0 replies
STACKD0E Sep 11, 12:19 PM
$ELOX 👁
0 replies
focafoca99 Sep 11, 11:51 AM
$ELOX started its Phase 2b EXACT study with the first two patients dosed in the Alport syndrome trial.
0 replies
AMFN_is_Holy_Grail Sep 3, 11:52 PM
$ELOX invest in AMFN It's Bitcoin 2.0 for investors. Be part of something special and get rich. Very rich. Be part of the first company which will commercialize electricity produced from fusion process.
0 replies
Theybleedred Aug 11, 2:46 PM
$ELOX here we go !!
0 replies
CamilaCruze Aug 7, 11:02 PM
$ELOX The Phase 2b Alport data is the key one. If exaluren produces convincing clinical results… ELOX could potentially be revalued dramatically because it's currently a clinical-stage company.
0 replies